Cerebrospinal fluid beta-2-microglobulin: a reliable index of leukaemic infiltration of central nervous system. 1986

S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi

Cerebrospinal fluid (CSF) beta-2-microglobulin (B2m) has been proposed as a marker of central nervous system (CNS) involvement in myelo-lymphoproliferative diseases. Recently its reliability has been put in question because of false positive and false negative results. In our study, B2m was measured in 574 CSF samples collected from 74 patients affected by ALL, ANLL or lymphomas; 20 of these patients had CNS-involvement while they were under observation. There was a significant difference in CSF B2m between the patients with and without CNS-involvement (p less than 0.001). No false positive or false negative results were obtained. In 4 cases the rising of CSF B2m was observed 8, 6, 4 and 4 wk before the clinical and laboratory diagnosis of CNS-involvement. In all patients the clinical and laboratory improvement of the neurological disease was associated with a progressive decrease of CSF B2m. Some hypotheses about the origin of CSF B2m are discussed. The authors conclude that CSF B2m is a useful and reliable marker of CNS-involvement in myelo-lymphoproliferative disease.

UI MeSH Term Description Entries
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002493 Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. CNS Disease,Central Nervous System Disease,Central Nervous System Disorder,CNS Diseases,Central Nervous System Disorders
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
July 1983, Cancer,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
April 1995, European journal of pediatrics,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
January 1992, Journal of clinical & laboratory immunology,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
May 1989, Zhonghua nei ke za zhi,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
May 1981, The New England journal of medicine,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
December 1989, Acta neurologica Scandinavica,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
July 1985, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
September 1987, Archives of neurology,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
January 2007, Saudi medical journal,
S Storti, and L Pagano, and R Marra, and L Teofili, and B M Ricerca, and G Leone, and B Bizzi
February 2022, Zhongguo shi yan xue ye xue za zhi,
Copied contents to your clipboard!